| Catalog No. | 
			TD-HF879036 | 
		
		
			| Species reactivity | 
			Human | 
		
		
			| Applications | 
			Research Grade Biosimilar | 
		
		
			| Host species | 
			Chimeric | 
		
		
			| Isotype | 
			IgG1, kappa | 
		
		
			| Expression system | 
			Mammalian Cells | 
		
		
			| Clonality | 
			Monoclonal | 
		
		
			| Target | 
			TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1 | 
		
		
			| Endotoxin level | 
			Please contact the lab for this information. | 
		
		
			| Purity | 
			>95% purity as determined by SDS-PAGE. | 
		
		
			| Purification | 
			Protein A/G, purified from cell culture supernatant. | 
		
		
			| Accession | 
			P01375 | 
		
		
			| Form | 
			Liquid | 
		
		
			| Storage buffer | 
			0.01M PBS,pH7.4. | 
		
		
			| Stability and Storage | 
			Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. | 
		
		
			| Alternate Names | 
			TA-650,cA2,CAS:170277-31-3 | 
		
		
			| Background | 
			Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research. | 
		
		
			| Note | 
			For research use only. Not for use in clinical or therapeutic applications. |